An Open Labeled, Single Arm (Non-Comparative), Prospective Phase I Clinical Study To Evaluate The Safety, Tolerability And Immunogenicity Of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed), 11-Valent Of Panacea Biotec Ltd. In Healthy 12-23 Months Old PCV- naive Toddlers
Latest Information Update: 09 Nov 2020
At a glance
- Drugs Pneumococcal vaccine conjugate 11 valent Panacea Biotech (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Panacea Biotec
Most Recent Events
- 04 Nov 2020 Status changed to completed.
- 27 Sep 2019 New trial record